Full Press Release Details
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced a poster presentation highlighting data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025 taking place December 5-7, 2025 in Singapore. The poster will focus on data in previously treated patients with HER2 exon 20 mutant NSCLC.
| Poster presentation details: | |
| Title: | Enozertinib (ORIC-114), a Highly Selective, Brain Penetrant |
| EGFR and HER2 Inhibitor, in Patients with HER2 Exon 20 | |
| Mutant NSCLC: Randomized Dose Optimization | |
| Presentation Number: | 981P |
| Session Type and Title: | Poster Display session and cocktail |
| Session Date & Time: | Friday, December 5, 2025; 5:15 – 6:15 p.m. SGT |
Full abstracts are available for public viewing via the ESMO Asia Congress website.
Conference Call and Webcast Details
In conjunction with the ESMO Asia Congress, ORIC will host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. A live webcast and audio archive of the conference call will be available through the investor section of ORIC’s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.
About ORIC Pharmaceuticals, Inc.